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Abstract
Dalton Michael Sheffield: Assessing the Effects of Antioxidants on Oxidative Stress in
Triple-Negative Breast Cancer Cells via Protein Carbonylation
Breast cancer is a highly complex, heterogeneous disease, and potential effective
treatment options are being continuously researched in order to provide a method of
halting cancer growth and metastasis. One area in particular involves alleviating
oxidative stress within cancer cells. Oxidative stress is generally defined as an imbalance
between oxidant and antioxidant species in favor of the oxidants. Cancer cells use this
oxidative stress to initiate carcinogenesis in cells through different mechanisms, and
protein carbonylation is a primary biomarker used to quantify oxidative stress levels.
Antioxidant compounds are those used to alleviate oxidative stress within cells. Here
breast cancer cells with compounds of varying antioxidant capacity in order to assess
their effectiveness in combating oxidative stress. After the cells were treated, their
proteins were extracted, and an oxyblot protocol was then performed to determine the
degree of protein carbonylation present in each sample. In the experiments, it was
observed that cells treated with vitamin E exhibited significant levels of oxidative stress,
and cells treated with CoQ10 and lovastatin exhibited little to no change in levels of
oxidative stress. The findings on vitamin E were of more interest because vitamin E has
been used as an antioxidant in the past, but the findings in this paper show it actually
enhanced protein carbonylation within cells.
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Chapter 1: Overview of Breast Cancer, Lipid Metabolism, and Oxidative Stress
1.) The Etiology and Treatment of Breast Cancer
A.) Etiology
Cancer is a major public health problem worldwide and the second leading cause
of death in the United States. For 2019, 1,762,450 new cancer cases and 606,880 cancer
deaths are projected to occur in the United States (Siegel 2019), approximately 4,800 new
cases and 1,700 deaths a day. Furthermore, breast cancer is the most frequently occurring
cancer among women. In 2015, there were an estimated 1,384,558 new breast cancer
diagnoses worldwide and nearly 459,000 breast cancer-related deaths (Tao 2015).
According to the American Cancer Society, approximately one in eight women will
develop breast cancer over the course of their life. Breast cancer is an extremely complex
and heterogeneous disease that is still not fully understood, even after years of research.
A meta-analysis of nine studies showed that hyper-methylation of BRCA1 gene is a high
risk factor for developing breast cancer (Tao 2015), which helps establish the foundations
of its notoriety as a genetic disease. However, while breast cancer is a genetic disease, its
inherited, genetic underpinnings are not the sole determinants of its pathology. Several
GWAS studies have shown that susceptibility genes and genomic sequences account for
less than one-third of all inherited breast cancers, with BRCA1 and BRCA2 accounting for
85% of all hereditary breast cancers (Althuis 2004). Although there are some genetic
elements of breast cancer that are well-defined in their impact, such as BRCA1 and
BRCA2, most of the women who develop breast cancer do not present a clear, concise
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risk profile, with only 5–10% of all breast cancers considered due to mutations in
inherited high penetrance (Althuis 2004). Instead, breast cancer is heavily influenced by a
combination of age, personal or family history, reproductive and hormonal factors, postmenopausal

obesity,

parity,

and

exogenous

hormone

use

alongside

genetic

predispositions. These factors will be discussed later in this chapter.
As previously stated, breast cancer is a heterogeneous disease that is affected by
non-genetic factors as much as genetic ones, so breast cancer’s genetic component is still
vital in understanding this complex disease. The most inherited breast cancer genes are
BRCA1 and 2. These genes facilitate the repair of DNA strand breaks and certain founder
mutations occur in the specific ethnic populations. BRCA2 associated tumors are of a
higher grade, ER-positive, and they are unlikely to express HER2 receptor as opposed to
BRCA1 which are mainly triple negative (Libson 2014). Genetic mutations also play a
role in both inherited and sporadic breast cancer. P53 mutations are present in nearly 40%
of human breast cancer acquired as a defect, with high penetrance genes being
responsible for 5%–10% of all breast cancers (Libson 2014). Overall, the etiology of
breast cancer cannot be concisely defined due to the heterogeneity of the disease process,
and dominant gene mutations appear to be present in only small numbers of breast
cancers, with the most common being BRCA1 and BRCA2. Instead, it is suggested that
gene variations due to single nucleotide polymorphisms, or SNPs, likely explain the
heterogeneous nature of breast cancer and the differences among individuals with regard
to tumor behavior (Tao 2015).
Several examples of non-genetic factors that significantly impact the likelihood of
developing this disease range from the age at which women conceive their first child to
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the use of exogenous hormones over the course of one’s life. Interestingly, the age at
which women conceive their first child also plays a substantial enough role in influencing
one’s risk of developing breast cancer. Delayed childbearing was more consistently
associated with an increased risk of developing ER-positive than ER-negative breast
cancers. The highest risks were observed among women conceiving their first child at a
later age, with risk estimates ranging from 1.4–2.6. In addition, three of the six studies
assessing joint PR/ER expression found very modest elevation in hormone receptorpositive, but not hormone receptor-negative tumors (Althuis 2004).
The age at which women experience menarche, the first occurrence of
menstruation, is also believed to affect one’s risk of developing breast cancer.
Epidemiological investigations suggested that breast cancer risk associated with a young
age at menarche was more pronounced among premenopausal women, and women who
did experience menarche at a young age were more likely to develop ER/PR positive
tumors than ER/PR negative ones. While older age at menarche was not differentially
associated with increased breast cancer risk when defined by ER or PR status, later
menarche was not associated with reduced risk of developing ER-negative/ER tumors in
five of the studies examined (Althuis et al. 2004). The associated risk for later menarche
was similar for ER-positive/PR-positive and ER-negative/PR-negative tumors as well. In
addition to age at menarche, women who experienced post-menopausal obesity were at
an increased risk to develop breast cancer. A consistent association between postmenopausal obesity and ER-positive/PR-positive tumors was identified in three of the
four studies (one cohort and two case-control) that assessed this relationship (reviewed in
Althuis et al. 2004). Furthermore, risk estimates increased incrementally with increasing
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BMI and reached statistical significance in two of the studies, and the Iowa Women’s
Health Study has also shown that post-menopausal obesity was associated with an
increased risk for hormone receptor-positive breast cancer, regardless of ER, PR, or
ER/PR joint status (Althuis 2004). Parity, or the number of times a woman carries a
pregnancy to a viable gestational age, is another non-genetic factor that impacts a
woman’s likelihood of developing breast cancer. The reduction in breast cancer risk
associated with parity was more consistently observed for ER-positive than ER-negative
tumors, and risk estimates ranged from 0.5-0.8, with the greatest reductions noted for
multiparous women. Although the small size of several studies limits the statistical power
of the analyses to find significant differences, the point estimates suggest that increasing
parity may reduce the risk of ER positive breast cancers (Althuis 2004). Exogenous
hormone usage via hormone replacement therapy or oral contraceptive use has modest
evidence as an external risk factor in increasing one’s risk of developing breast cancer.
Recent oral contraceptive use was more strongly associated with ER-negative tumors
than ER-positive tumor subtypes in two the investigations examined (Althuis 2004). The
Nurses’ Health Study did not find an increased risk for breast cancer among current
users, but it did report a stronger association of past use of postmenopausal hormones
with ER-positive tumors (Althuis 2004). Given the information presented above, the
complex, heterogeneous nature of breast cancer gives the reader valuable insight into
why this disease is not only so prevalent throughout the world but difficult to manage due
to its variety of external influences.
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B.) Malignant Progression
Malignant progression of breast cancer and how said progression comes to
fruition is a unique aspect of cancer in general. Cancer impacts the body at the most
fundamental level by altering cells and their associated mechanisms. Normally, cell
proliferation functions as a means of replacing dead or defective cells. The means by
which these cells grow and divide are tightly regulated by many intracellular
mechanisms. However, cancer cells escape the control of these regulators and proliferate
uncontrollably. This phenotype is also associated with diminished cell death, invasion of
surrounding tissues, and metastasis throughout the body using the vascular and lymph
systems. Before cancer cells can metastasize, they form an abnormal mass of tissue called
a tumor, or neoplasm. Most tumors grow as solid masses comprised of two distinct,
interdependent compartments called the parenchyma and the stroma. The parenchyma
consists of the neoplastic cells of the tumor while the stroma is connective tissue, blood
vessels, etc. that provides tumors with nourishment and aids in the removal of waste
products. Tumors experience temporally unrestricted growth into the surrounding tissues
with the ability to grow in at least three different tissue compartments: the original
compartment, the mesenchyme (tumor invasion), and a distant mesenchyme (tumor
metastasis). Tumors are typically classified as cancerous once they invade the
surrounding mesenchyme, which is characteristic of the transition from normal
epithelium to cancer.
Tumorigenesis is not an immediate change, but instead, it is the result of a multistep process in which cancer cells shift from a normal, benign phenotype to a malignant
one. This process is a slow one that typically occurs over many years. In order to transit
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from normal epithelium into cancer, breast cells undergo this multi-step process
beginning with the change from normal tissue to intraductal hyperplasia, in which the
cells still appear very close to normal. From there, cells become an intraductal
hyperplasia with atypia, with cell shape becoming more irregular and distorted. After this
stage, the tumor undergoes the transition into intraductal carcinoma in situ and is now
classified as cancerous, even though it has yet to invade any new tissues. Lastly, tumors
become invasive cancers, and at this step, the tumors either invade the local mesenchyme
or metastasize to other areas of the body. In order to describe how these metastases arise,
one must address the complexities of the invasion-metastasis cascade. The answer to how
cancer cells acquire the ability to complete the steps required to metastasize seems to
depend on the fact that cancer cells appropriate complex biological programs that play
roles in normal cell and organismic physiology (Weinberg 2008). In this instance, the
specific normal biological process involves the epithelial-mesenchymal transition (EMT),
which plays key roles in many steps of normal morphogenesis. Cells are required to
undergo this transition because true epithelial cells are incapable of translocating to a
distant region of the body, so cells are required to shed certain epithelial traits in favor of
mesenchymal traits, which allow for locomotion and invasion of the extracellular matrix.
The process of EMTs can be programmed by a variety of transcription factors
(TFs) that are activated transiently in various stages of embryogenesis and throughout the
embryo. The transient expression of these TFs indicates that cells will maintain their
mesenchymal form while said transcription factors are active, but cells will revert to their
ground state in the absence of these TFs. Although the brief description of EMT
presented does not readily indicate the relevance to cancer cells, two key aspects of
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carcinoma cells point to the relevance these embryonic programs and TFs have to tumor
progression. First, many of the phenotypic traits of embryonic cells are recapitulated by
aggressive carcinoma cells. Second, many of the embryonic TFs that are known to play
critical roles in orchestrating EMTs during embryogenesis are expressed in a variety of
human tumor cells. In fact, their expression is often correlated with aggressive tumor
cell-associated traits (Weinberg 2008). During embryogenesis, the expression of various
EMT-inducing TFs appears to occur in response to certain contextual signals that are
released by nearby cells. It seems likely that the same type of heterotypic signals impinge
on various carcinoma cells during the process of carcinoma progression. It also seems
that, in general, none of these ligands is, on its own, capable of triggering EMT; instead,
in many circumstances, they seem to act in coordination to provoke EMT in nearbycarcinoma cells. However, the rules that define these interactions are still unexplored
(Weinberg 2008). As for the context of carcinoma pathogenesis, it is likely that these
heterotypic signals are released by mesenchymal cells that form the tumor-associated
stroma. These mesenchymal cells have a different origin than the carcinoma cells that
became mesenchymal via EMT. These stromal cells are recruited either from the stroma
of the tissue in which the tumor arises or, alternatively, from the bone marrow, which
appears to generate a number of distinct types of mesenchymal progenitor cells that are
released into the circulation and become available for local recruitment by carcinoma
cells. Such cells appear to enter into the tumor-associated stroma and thereafter
differentiate into a variety of mesenchymal cell types, including myofibroblasts and
endothelial cells. In fact, the stroma of most carcinomas is assembled from a variety of
mesenchymal cell types whose precise origins are still quite unclear (Weinberg 2008).
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The fact that heterotypic signals may induce an EMT in carcinoma cells reveals another
important aspect of malignant progression: these cells do not need to undergo additional
genetic changes in order to acquire the cellular phenotypes associated with high-grade
malignancy. Instead, when confronted with an appropriate mix of contextual signals,
primary carcinoma cells will develop such phenotypes without suffering additional
mutations (Weinberg 2008). The fact that carcinoma cells that undergo an EMT adopt
mesenchymal phenotypes and invade into the tumor stroma and then into adjacent normal
tissues creates an experimental difficulty, since these invading neoplastic cells are, at
least superficially, indistinguishable from the true mesenchymal cells that surround them
in the tumor stroma and, later on during the course of invasion, in the stroma of normal
tissues lying outside the initial margins of tumors. This complication has caused some
pathologists to dismiss the EMT as a laboratory artifact (Weinberg 2008). It seems likely,
however, that this controversy will be settled, sooner or later, because of two factors.
First, it is probably the case that most carcinoma cells undergoing an EMT do so
incompletely, i.e. by partially shutting down epithelial markers (such as E-cadherin and
cytokeratins) while acquiring mesenchymal markers (such as N-cadherin, vimentin and
fibronectin). Accordingly, future attempts at finding cells co-expressing both epithelial
and mesenchymal markers are likely to reveal the invading neoplastic cells hiding among
the true mesenchymal cells in the stroma (Weinberg 2008). A second fact is likely to help
reveal otherwise occult cancer cells that have undergone an EMT: carcinoma cells that
have passed through an EMT express certain markers that appear not to be expressed by
true mesenchymal cells. These two factors should reveal the elusive wolves hiding in
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sheep's clothing—the invasive carcinoma cells present in small nests and large aggregates
in the otherwise-normal tissues of carcinoma patients (Weinberg 2008).
Given current knowledge, it is plausible that the expression of one of these TFs
should enable a primary tumor cell to invade locally, intravasate, survive in the
circulation, extravasate and survive for a limited period of time in the parenchyma of a
foreign tissue in which it has landed. The subsequent fate of such a disseminated cell is
less clear, however. Thus, a breast cancer cell landing in the brain, the bone marrow, or
the liver must confront an array of extracellular matrix components, signaling molecules
and stromal cell types to which it is, at least initially, poorly adapted (Weinberg 2008).
This lack of instantaneous compatibility between newly arrived cancer cells and their
newfound homes is likely to explain the very low success rate of the last step of the
invasion–metastasis cascade—the growth of a micrometastasis into a macroscopic
metastasis that is, as mentioned, termed colonization. It is apparent that only a small
number of micrometastases out of the thousands that are initially seeded ever succeed in
growing into a macroscopic metastasis. It also seems apparent that colonization is not a
problem that is readily addressed by the multiple traits programmed by an EMT-inducing
TF (Weinberg 2008). To be sure, the increased resistance to apoptosis associated with an
EMT program should increase the survival of the cells within a micrometastasis. This
acquired trait does not, however, deal with the fact that these cells are otherwise
maladapted to the foreign microenvironment of the tissue in which they have landed
(Weinberg 2008).
Mechanisms of the sort depicted here, involving components of the EMT
program, may ultimately serve to explain how carcinoma cells are able to leave the
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primary tumor and ultimately arrive at distant anatomical sites. It is unclear at present
whether aggressive tumors arising from different embryonic cell lineages, specifically
hematopoietic, neuroectodermal and mesenchymal tumors, deploy the same set of
mechanisms or whether their metastatic dissemination depends on an entirely different
set of factors and molecular mechanisms. Indeed, at present, it remains possible that the
motility and invasiveness of some carcinomas derives from mechanisms that have
nothing whatsoever to do with the EMT, although it is suspected otherwise (Weinberg
2008).
C.) Diagnosis/Treatment
It is important to consider how cancer is not only diagnosed but also treated once
a diagnosis has been made. An important method in diagnosing and treating breast cancer
is screening. Screening is considered the one of the most important public health
strategies to reduce mortality from breast cancer (Libson 2014). For example, along with
increased rates of screening, the rates of incidence of early stage cancers has increased
dramatically, and in turn, a reduction in mortality has been observed as well (Libson
2014). Breast cancer screening can be performed through a plethora of tests with ranging
specificity, but only four will be focused on: mammography, MRI, breast biopsy, and
HER-2/neu detection assay. Mammography has been the hallmark test for breast cancer
screening for years. Mammography is the use of X-rays in order to capture a picture of
the breast, and over the years, digital mammography has replaced conventional (film)
mammography in some screening services. Digital provides advantages over
conventional (film) mammography through the use of computer-aided detection and
algorithm-based computer programs that alert the radiologist to possible abnormalities.
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With that being said, mammography should not be frequently used due to potential
radiation risk (Nounou 2015). Magnetic resonance imaging (MRI) is another method
used in the diagnosis of breast cancer. While not a method routinely used in conventional
diagnosis, MRI is considered a useful adjunct to diagnostic mammography by the
National Comprehensive Cancer Network, if needed in certain situations (Nounou 2015).
The MRI method is valuable in the screening of selected high-risk patients, patients in
whom breast augmentation prevents effective screening mammography, or patients with
equivocal findings on other imaging modalities (Shah 2014). However, due to its poor
selectivity and dependence on contrast media, MRI is typically only used in a
supplementary role in the diagnosis of breast cancer. Although mammography and MRI
are useful in diagnosing breast cancer, the only definitive method for diagnosing breast
cancer is with a breast biopsy. To ensure the elimination of false negative results and
increase diagnostic accuracy, clinical breast examination, breast imaging, and breast
biopsy are performed simultaneously. Needle biopsies are the method used in diagnosis,
and they consist of two methods: fine needle aspiration cytology (FNAC) and core needle
biopsy (CNB). The FNAC method is the least invasive type, using a thin hollow needle to
extract cells from the suspicious lesion. The CNB method used a larger needle and
removes a small cylinder of tissue about the size of a grain of rice from the lesion, with
about three to five cores being removed. In both methods, samples are sent to the
laboratory in order to determine malignancy (Nounou 2015). One of the last, more novel
methods used to diagnose breast cancer is HER-2/neu detection assay. This assay is an
immunohistochemistry technique (IHC) that uses antibodies as a tool to detect protein
expression. Monoclonal or polyclonal antibodies complementary to the antigen of interest
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are labeled with a marker, allowing detection of the antibodies bound to regions of
protein expression in a tissue sample (Nounou 2015).
After the diagnosis of an individual has been reached, determining the method of
treatment becomes the next issue. Prognostic and predictive factors aid in diagnosing and
determining the treatment protocol for breast cancer patients, which makes them valuable
tools. Prognostic factors are clinical or biological characteristics that are objectively
measurable and provide information on the likely outcome of the cancer disease.
Predictive factors, on the other hand, are clinical or biological characteristics that provide
information on likely benefit from a specific treatment. For example, status of the lymph
nodes is one of the single most important prognostic factors, and overall survival
significantly decreases as the number of affected lymph nodes increases.
Tumor size is the second most valuable prognostic factor, and a larger size tumor
is equated with a worse prognosis (Libson 2014). Even though estrogen receptor (ER)
and progesterone (PR) receptor status are considered weak prognostic indicators, they are
the strongest predictive factors for response to endocrine therapy, and as such, ER and PR
assays should be performed on all breast cancers (Shah 2014). Another important
prognostic factor for breast cancer treatment is the HER-2 protein expression and gene
amplification. The HER-2 proto-oncogene encodes for a transmembrane tyrosine kinase
growth receptor. The overexpression of HER-2 is a prognostic factor for outcomes in
both node-negative and node-positive patients, and furthermore, it is also a predictive
factor for response to certain therapies that target HER-2 receptors (Shah 2014).
After the final diagnosis and analysis of all prognostic and predictive factors,
treatment options can finally be considered. The main types of treatment for breast cancer
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are surgery, endocrine therapy, radiation therapy, and chemotherapy. In the case of
surgery, it is always followed by adjuvant therapy in order to ensure full recovery and
minimalize the risk of metastases. Because certain cancer cells may not be seen during
surgery, adjuvant therapy works to minimalize the risk of local recurrence of cancer cells
as well. Mastectomy is the go-to surgical method, and approximately 30%–40% of breast
cancer patients in the United States are candidates for mastectomy. There are different
levels of invasiveness to mastectomies. A total mastectomy (TM) involves the complete
removal of the breast. Skin-sparing mastectomy (SSM) is similar to TM, but the
procedure spares as much skin as possible. Nipple-saving mastectomy (NSM) is similar
to SSM, but in this instance, the areola or nipple is saved as well. Lastly, the most
invasive mastectomy is radical mastectomy (RM). This version involves the complete
removal of the pectoralis muscles and level III axillary nodes (Shah 2014).
Alternatively, endocrine therapy (ET) is rather straightforward in that its goal is
either to balance or block hormones in cancer cells. ET is indicated in all patients with
detectable ER expression, and the choice of medication is determined by the patient’s
menopausal status (Nounou 2015). Radiation therapy (RT) is a process in which cancer
cells are directly exposed to high levels of radiation, but there are significant side effects
of RT on the skin. These include decreased sensation in breast tissue, skin problems in
treated area, and at the end, the skin may become moist and weepy (Nounou 2015).
Lastly, chemotherapy (CT) is simply the use of chemical agents in treating breast cancer.
The benefit from CT is more pronounced in ER-negative tumors, and it is recommended
in the vast majority of triple-negative breast cancer (TNBC), HER-2 positive cancers, and
in high-risk luminal tumors. Overall, CT regimens based anthracyclines and taxanes
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reduce breast cancer mortality by about one-third. CT is also used in neoadjuvant therapy
in order to reduce tumor size before surgery when the tumor is inoperable due to size.
Although CT is a hallmark treatment for breast cancer, it has serious negative health
effects in addition to side effects such as hair loss, neutropenia, and depressed immunity
(Nounou 2015).
Because of the significant adverse effects of treatments like chemotherapy and
radiation therapy, the development of selective drug delivery systems and novel treatment
carriers have become something of a necessity. These drug delivery systems are an
important approach with tremendous potential in overcoming problems associated with
systemic toxicity. Targeted drug delivery systems for antitumor drugs have demonstrated
great potential to lower cytotoxicity associated with typical treatments and increase the
associated therapeutic effects. Targeting can occur through either passive or active
targeting (Nounou 2015). Passive targeting relies on taking advantage of the chemical
and physical properties of cancer tissue. Cancer tissues have large fenestrations in the
cancer vasculature resulting from imbalance angiogenesis, which are wide enough to let
large nanoparticles pass and accumulate within the cancer tissue. This vascular
permeability is referred to as enhanced permeability and retention effect (EPR). This EPR
effect is the main concept of passive targeting for tumor selective delivery of
macromolecular drugs. However, the EPR effect is frequently inhomogeneous in tumor
tissue, and this heterogeneity of the EPR effect may reduce the tumor delivery of
macromolecular drugs (Nounou 2015). Active targeting is the other aspect of targeted
drug delivery, as it was proposed for its improved targeting efficacy. Active targeting
involves a targeting moiety such as a protein or antibody that is either conjugated to the

14

nanoparticulate system or the drug moiety directly targeting specific receptors on the
cancer cell. An overexpression of receptors or in antigens in cancer acts as a potential
target to achieve efficient drug uptake via receptor-mediated endocytosis (Nounou et al.
2015). With modern medicine and science rapidly advancing, the increasing number of
possibilities and combinations that can be used to create effective treatment methods
should provide breast cancer patients with optimism in knowing progress is being made.
D.) Drug Resistance
Quite possibly the biggest obstacle facing scientists today is the development of
resistance to anticancer drugs by cancer cells. With the development of safe and effective
new drugs taking years, scientists and physicians are beginning to run out of options for
treating individuals with breast cancer. Cancer cells exhibit the incredible ability to
continuously adapt to new drugs and treatment regimens, and finding ways to circumvent
this resistance is markedly difficult. A major component of intrinsic drug resistance in
cancer cells involves tumor heterogeneity. Intra-tumor heterogeneity can be observed at
many different levels of cancer and may be assignable to a number of different factors
that primarily occur at the cellular level. Genomic instability creates a significant
intercellular genetic heterogeneity in cancer, and genotypic changes that can arise from
such instability and affect tumor heterogeneity include: mutations, gene amplifications,
deletions, and chromosomal rearrangements, just to name a few. These factors can
change, increase, or diminish gene products, which are directly involved in the generation
of drug resistance and poor prognosis (Mansoori et al. 2017). The tumor
microenvironment is also thought to play a key role in the generation of resistance against
anti-cancer drugs. The tumor microenvironment involves stromal cells, extracellular
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matrix, and several soluble factors, such as cytokines and growth factors. Tumor-tumor
cell communication, tumor-stromal cell communication, as well as tumor-ECM interface,
all contribute to direct cell interaction mediated by drug resistance. Moreover, growth
factors and cytokines produced in the tumor microenvironment provide additional signals
for tumor cell growth and survival (Mansoori 2017).
Cancer stem cells present yet another pivotal element in the production of drug
resistance in cancer cells. Although chemotherapy impairs a tremendous number of cells
in tumors, it is understood that chemotherapeutic agents are removed from cancer stem
cells through special mechanisms. For instance, with overexpression of the ATP-binding
cassette, drug transporters such as ABCB1 and ABCG2 have been shown to keep cancer
stem cells away from chemotherapeutic agents (Monsoori 2017). In addition, cancer stem
cells share common traits with normal stem cells, such as active DNA repair capacity,
resistance to drugs and toxins, resistance to apoptosis, and hypoxic stability. With these
mentioned features, these cells remain stable in patients who appear to be recovering or
can metastasize to distant organs and cause cancer recurrence (Mansoori 2017). Due to
the nature of cancer stem cells, finding and targeting populations of them in tumors could
have a major impact in decreasing tumor resistance. Multi-drug resistance (MDR) in
cancer chemotherapy has been pointed out as the ability of cancer cells to survive against
a wide range of anti-cancer drugs. MDR works by not only increasing the amount of drug
released outside of the cell but also reducing the amount of chemotherapy agent absorbed
by the cell. Cancer cells increase the amount of drug released outside of the cell by using
a family of ATP-dependent transporters that are involved in transporting nutrients and
other molecules across the membrane. These ABC transporters are composed of two
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cytoplasmic domains that bind to ATP known as the ATP binding cassette (ABC) and
two transmembrane domains. The P-glycoprotein (PGP), which is an ABC family
member, is a multidrug membrane transporter that is normally known as a pump for
moving chloride out of cells, but it can also bind to a variety of chemotherapy agents.
Following the binding of these agents, ATP is hydrolyzed and the structure of P-gp is
altered, and as a result, the agent is released into the extracellular space. After a second
ATP molecule is hydrolyzed, the transporter is able to return to its original structure and
is ready to release the drug outside of the cell (Mansoori 2017). Besides increasing the
amount of drug released outside of the cell, cancer cells are also able to reduce the
amount of drug absorbed. This can occur by reducing the tendency of drugs to bind to
receptors or by reducing the number of receptors. Some agents require specific
transporters in order to enter cells, and mutations in these transports can inhibit them,
thereby reducing the absorption of the drug (Monsoori 2017).
Finally, one of the most important mechanisms in altering drug resistance comes
in the form of epigenetic alterations. These alterations occur through methylation of DNA
and histone alterations. DNA methylation is a major epigenetic phenomenon occurring
when cytosine is methylated at the 5’ carbon in the CpG islands (an upstream of
promoters), but it can occur throughout the genome in other positions as well. For
example, tumor suppressor genes are often silenced by methylation of their promoters,
yet hyper-methylation of oncogene promoters induces transcription. Demethylation of the
multi-drug resistance gene (MDR1) leads to the acquisition of the multi-drug resistant
phenotype and reduces the accumulation of anti-tumor drug in cells (Monsoori 2017). As
scientists and physicians scramble to find new and innovate ways to combat cancer drug

17

resistance, only time will tell whether their labors will bear the fruit needed to accomplish
such a daunting task.

2.) Fatty Acid Synthesis and Lipid Metabolism in Breast Cancer
Even though cancers are hugely diverse in classification and etiology, cancerous
cells predominantly share the attribute of metabolic abnormalities. In cancer cell
metabolism, the most commonly thought of abnormality pertains to the Warburg effect.
The Warburg effect describes glucose metabolism within cancer cells, in which
glycolysis is decoupled from pyruvate oxidation, and in doing so, carbon from glucose is
used to build other molecules instead of completely oxidizing them to carbon dioxide
(Currie et al. 2013). Because of this, cancer cells are unable to produce the maximum
amount of ATP possible via mitochondrial respiration, despite high oxygen availability.
During normal cellular metabolism in the presence of oxygen, glucose molecules undergo
glycolysis in order to form pyruvate, and after pyruvate enters the mitochondria, it is
oxidized to acetyl-CoA, which then enters the Krebs cycle to produce the reducing
equivalents needed for oxidative phosphorylation. However, cells in oxygen limiting
environments ferment pyruvate to lactate. Normal cells, however, preferentially use
oxidative phosphorylation because it yields ~36 ATP molecules, whereas anaerobic
glycolysis produces two ATP molecules. The Warburg effect is the use of fermentation in
aerobic conditions and is characterized by an increase in glucose uptake and
consumption, a decrease in the rate of oxidative phosphorylation, and the production of
lactate (Currie et al. 2013).
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Alterations in fatty acid (FA) metabolism in cancer cells have received less
attention over the years but are increasingly being recognized, especially in breast
cancers due to breast tissues’ high adipose content. Fatty acids (FAs) are molecules that
consist of a terminal carboxyl group and a hydrocarbon chain that can be either saturated
or unsaturated. Fatty acids are pivotal for energy storage, membrane proliferation, and the
generation of numerous signaling molecules in the body. Fatty acid/lipid metabolism is
another aspect of normal cell metabolism that is altered in cancer cells and other rapidly
proliferating cells. In cancer cells, carbon is diverted from energy production to FAs for
biosynthesis of membranes and signaling molecules, and all lipids are derived in part
from acetyl-CoA with many containing FAs. The building blocks for fatty acids can
come from either exogenous sources or de novo synthesis. While most normal cells
prefer exogenous sources, tumors synthesize FAs de novo and often exhibit a shift toward
FA synthesis (Currie et al. 2013). Within cells, fatty acids have many different fates,
including being incorporated into membrane, storage, or signaling lipids, or oxidized to
carbon dioxide as an energy source.
Fatty acid synthesis is an anabolic process that starts from the conversion of
acetyl CoA to malonyl CoA by acetyl CoA carboxylase. Malonyl CoA is then committed
to fatty acid synthesis (FAS) and is involved in the elongation of fatty acids through fatty
acid synthase (FASN). Additional modifications of fatty acids can be carried out by
elongases and desaturases (Arkaitz et al. 2013). The fatty acids produced in cancer cells
play an important role in cell invasion and metastasis. Many of signaling molecules
composed of fatty acids promote cell migration and metastasis, and one of the ways cells
accomplish this is through induction of EMT by transforming growth factor-β (TGF- β)
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(Röhrig et al. 2016). The induction of EMT requires complex remodeling of cellular lipid
composition to facilitate changes in membrane fluidity required for cell migration.
Treatment of breast cancer cells with compounds that disrupt a gene expression signature
associated with EMT reduced membrane fluidity and blocked migration and lung
metastasis formation after tail vein injection in mice (Röhrig et al. 2016). Interestingly,
the effect on membrane fluidity was abolished after addition of oleic acid, which disrupts
the dense packing of saturated acyl chains. Oleic acid also restored metastasis formation
in vivo, suggesting that monounsaturated FAs promote this crucial step during tumor
progression (Röhrig et al. 2016).
The alterations in lipid metabolism and fatty acid synthesis in cancer cells are also
due to genetic aspects of cancer cells. The transcription of genes involved in fatty acid
synthesis is regulated by the sterol regulatory element-binding protein 1 (SREBP-1)
transcription factor, which regulates not only the enzymes needed to convert acetyl-CoA
into fatty acids but also the enzymes of pentose phosphate pathway and the pathways
required to convert acetate and glutamine into acetyl-CoA. SREBP-1 also not only
regulates cholesterol biosynthesis but genes encoding proteins that catalyze or facilitate
fatty acid synthesis (DeBerardinis et al. 2016). Both fatty acids and lipids can also be
acquired from the extracellular space to supply membrane biosynthesis. The process of
PI3K signaling activates fatty acid uptake and suppresses fatty acid oxidation, thereby
maximizing lipogenesis in proliferating cells under the control of growth factors. Lipid
uptake becomes extremely important under metabolic stress, when the ability to meet
oncogene-driven demands for biosynthesis is compromised. The ability to scavenge
lysophospholipids (lipid intermediates containing a glycerophosphate backbone with one
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acyl chain) is a trait required for maximal cancer cell growth during hypoxia, as de novo
fatty acid synthesis from glucose is suppressed under hypoxic conditions (DeBerardinis
et al. 2016). Furthermore, in cancer cells with constitutive mTORC1 signaling, hypoxia
induces a state of dependence on access to extracellular desaturated fatty acids to
maintain

endoplasmic

reticulum

integrity

in

support

of

protein

biosynthesis (DeBerardinis et al. 2016). Although cancer cells activate de novo FA
synthesis, they also require the uptake of essential FAs. For example, α-linoleic acid and
linoleic acid carry double bonds beyond position 9 of the acyl chain; these cannot be
synthesized by humans and have to be provided by diet. Essential FAs are important for
multiple cellular functions, including the synthesis of signaling lipids and
phosphoglyceride species found in lipid rafts (Röhrig et al. 2016). Evidence for the
importance of essential FAs for tumor growth comes from a recent study that investigated
lipid composition of prostate tumors using Raman spectroscopy. This study found that
aggressive prostate cancers showed high numbers of lipid droplets containing cholesteryl
esters (CEs). This was due to increased expression of sterol O-acyltransferase 1 (SOAT1,
also known as ACAT1), which catalyzes the conversion of free cholesterol into CE and
its subsequent storage in lipid droplets. Through this mechanism, cancer cells prevent the
accumulation of free cholesterol, which would normally block expression of the LDLR
through sterol-dependent inhibition of SREBP (Röhrig et al. 2016).
With the importance of lipid metabolism and fatty acid synthesis in breast and
other cancers having been established, targets and potential treatment options that can
effectively limit cancer cell access to lipids and potentially inhibit their rate of metastasis.
This goal could be achieved through several different methods: blocking fatty acid
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synthesis, increasing fatty acid oxidation, diverting fatty acids to storage, or decreasing
fatty acid release from storage (Currie et al. 2013). Blocking fatty acid synthesis is
essentially the most effective and simplest method to reduce fatty acid levels in cancer
cells. ATP citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, and acyl-CoA
synthetases are all enzymes that would decrease fatty acid availability if inhibited. More
importantly, many of the inhibitors for these enzymes have minimal effects on noncancer cells, increasing the clinical significance of this method. Another method of
reducing fatty acid levels would be to reduce expression of the enzymes at the
transcription level. Inhibiting SREBP, the master transcriptional regulator of FA
synthesis, in cancer cells could decrease FA synthesis gene expression and possibly
prevent cancer cell proliferation (Currie et al. 2013). The second method to limiting fatty
acid access is increasing the degradation of fatty acids. The FAs are broken down by
mitochondrial β-oxidation. In this method, fatty acids are repeatedly cleaved to produce
acetyl-CoA that feeds into the Krebs cycle. This method is beneficial in theory, but data
from experiments testing this theory has produced mixed results (Currie et al. 2013). The
third method involves diverting fatty acids to storage. Most cells store FAs as TGs in
lipid droplets (LDs), an organelle whose major function is lipid storage, and while
increased number of LDs have been reported in many cancer cells, their role in cancer is
still unclear. The last method to mediate the amount of fatty acids cancer cells can access
is blocking fatty acid release from storage. Once stored, fatty acids can be released for
use by specific lipases, by preventing lipolysis, the available FA pool available for cancer
cells might be decreased, especially since FAs derived from lipolysis can also serve as
precursors for important signaling lipids (Currie et al. 2013).
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Although the importance of lipid synthesis for the proliferation and survival of
cancer cells is well established, much less is known about the role of β-oxidation in
cancer. However, several reports have demonstrated that cancer cells require β-oxidation,
particularly under stress conditions (reviewed in Röhrig et al. 2016). For example, the
brain-specific carnitine palmitoyltransferase 1C (CPT1C) is induced by adenosine
monophosphate-activated protein kinase (AMPK) in response to metabolic stress in
cancer cells to support energy generation when glycolysis is inhibited by rapamycin
treatment. More recently, it was shown that β-oxidation is an important bioenergetics
pathway in triple-negative breast cancer and is required for the activation of protooncogene tyrosine-kinase Src (Src). Targeting this pathway may limit the metabolic
flexibility of cancer cells and should be considered as a strategy for cancer treatment
(Röhrig et al. 2016). The oxidative degradation of fatty acids produced in cancer cells
also serves as a vital source of NADPH within these cells. The NADPH exerts two main
functions within cells. It provides redox power to counteract oxidative stress, which has
proved to be crucial for cancer cell survival in conditions of metabolic stress. On the
other hand, it is a coenzyme for anabolic enzymes, and thus, it is key for the generation of
new building blocks to sustain cell growth and proliferation (Arkaitz et al. 2013).
Fatty acid synthesis and lipid metabolism in cancer cells play a crucial role in the
pathogenesis of tumors and metastatic potential of cancer cells. Furthermore, both retain
crucial roles in oxidative stress and protein carbonylation as well, and the scope of how
lipid metabolism and fatty acid synthesis affect both processes is both complex and vast.
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3.) Oxidative Stress and Protein Carbonylation
The generation of reactive oxygen species (ROS) and nitrogen species
unrestrained, and subsequent oxidative stress, has been implicated in the pathogenesis of
many diseases, as well as aging in general (Lee et al. 2017). Oxidative stress can be
broadly defined as an imbalance between oxidants and antioxidants in favor of the
oxidants, which can potentially lead to damage. If the level of reactive species is high and
overcomes the antioxidant defense mechanisms of the body, oxidative damage can occur
to lipids, proteins, or directly to DNA. This DNA damage has been hypothesized to play
an important role in the initiation of carcinogenesis. The mechanisms surrounding
oxidative stress are involved in the activation of cell signaling pathways, including tumor
proliferation, increased tumor cell migration, and increased tumor cell proangiogenic
factors, and play a key role in apoptosis, mechanisms that can impact both cancer
progression and metastasis. Furthermore, reactive oxygen species and the resulting high
oxidative stress are key characteristics of malignant tumors (Lee et al. 2017).
Oxidative stress is not limited to one mechanism and may occur via more than
one pathway. In addition, oxygen radicals are not only generated in the mitochondria but
also by neutrophils and macrophages that produce ROS via a plasma membrane bound
nicotinamide adenine dinucleotide phosphate, reduced form (NADPH)-oxidase. The
radicals are generated for cell killing and bactericidal activities, but the NADPH-oxidase
is not exclusive to these cells. A panel of human tumor cell lines was shown to produce
large quantities of hydrogen peroxide in vitro (Brown and Bicknell 2001). The hydrogen
peroxide production was prevented by diphenyleneiodonium, which is an inhibitor of the
flavoprotein component of the NADPH-oxidase. Tumor cells may overproduce ROS
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because the NADPH-oxidase is regulated by the GTPase Rac1, which is itself
downstream of the proto-oncogene Ras (Brown and Bicknell 2001). Carcinoma cell
oxidative stress can also be induced by thymidine phosphorylase, an enzyme that is
overexpressed in the majority of breast carcinomas. Thymidine phosphorylase catabolizes
thymidine to thymine and 2-deoxy-D-ribose-1-phosphate; the latter is a very powerful
reducing sugar that rapidly glycates proteins, generating oxygen radicals within the
carcinoma cell. Thymidine phosphorylase activity induces carcinoma cell oxidative stress
in vitro (Brown and Bicknell 2001), and the frequent upregulation of thymidine
phosphorylase in human breast tumors suggests that this may be an important cause of
oxidative stress in breast cancer. Oxidative stress within breast carcinoma may also be
caused by a breast specific mechanism, namely the metabolism of estrogenic hormones
by lactoperoxidase. Lactoperoxidase, an enzyme that is produced within the mammary
gland, catalyzes the one-electron oxidation of 17 β-estradiol to a reactive phenoxyl
radical (Brown and Bicknell 2001). Inadequate vasculature within a tumor also possesses
the ability to induce oxidative stress in cancer cells. As a breast tumor rapidly outgrows
its blood supply, the cells become deprived of glucose and undergo hypoxia. This glucose
deprivation was shown to rapidly induce cellular oxidative stress within the MCF-7 cell
line, but it did not in any of the non-transformed cell lines. This may be because glucose
deprivation reduces intracellular pyruvate within the breast carcinoma cell, which
prevents the decomposition of endogenous oxygen radicals (Brown and Bicknell 2001).
Infiltration of macrophages in the tumor cells can also induce oxidative stress, as tumorassociated macrophages deliver sublethal oxidative stress to murine mammary tumor
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cells. In addition, tumor necrosis factor-α is secreted by tumor-associated macrophages
and induces cellular oxidative stress (Brown and Bicknell 2001).
The consequences associated with oxidative stress within carcinoma cells are
numerous as well. Oxygen radicals are powerful DNA damaging agents, and as a result,
ROS cause strand breaks, alterations in guanine and thymine bases, and sister chromatid
exchanges. These effects may inactivate additional tumor suppressor genes within tumor
cells or further increase expression of proto-oncogenes. Therefore, persistent genomic
instability due to oxidative stress will increase the malignant capacity of the tumor.
Sublethal oxidative stress, similar to that administered by macrophages, promotes cell
proliferation in vitro, with both superoxide and hydrogen peroxide stimulating growth
(Brown and Bicknell 2001). Proliferation in response to hydrogen peroxide may be due to
the activation of mitogen-activated protein kinases (MAPKs). When HeLa cells are
treated with hydrogen peroxide they undergo a sustained activation of all three MAPK
pathways: extracellular signal related protein kinase, c-Jun amino-terminal kinase/stressactivated protein kinase, and p38 (Brown and Bicknell 2001). Hyperphosphorylation of
c-Jun by oxidative stress activates activator protein-1 in MCF-7 breast carcinoma cells, a
response that stimulates proliferation, and multidrug-resistant human breast carcinoma
cells rapidly activate extracellular signal related protein kinase-2 when stressed by
glucose deprivation (Brown and Bicknell 2001). In addition, ROS may trigger mitosis via
MAPK independent mechanisms. Oncogenic Ras causes ROS production by activating
Rac1 and the NADPH-oxidase. In Ras-transformed human fibroblasts, ROS drive cell
cycle progression without the activation of MAPK pathways (Brown and Bicknell 2001).
Severe oxidative stress leads to apoptosis within cells, cancerous or otherwise.
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Conversely, persistent oxidative stress at sublethal levels may lead to acquired resistance
against apoptotic mechanisms within cancer cells. The induction of cell death by ROS is
dependent upon p53. Constitutive oxidative stress within breast carcinoma cells may
therefore accelerate the selection of p53 knockout tumor cell clones, which have an
apoptosis resistant phenotype (Brown and Bicknell 2001). Persistent oxidative stress may
also cause adaptive responses within the tumor cell that confer resistance to apoptosis.
The thiol antioxidant thioredoxin and metallothionein are rapidly upregulated in response
to oxidative stress, and the antioxidants malondialdehyde, superoxide dismutase,
glutathione peroxidase and catalase show increased expression or activity in breast tumor
tissue as compared with normal controls (Brown and Bicknell 2001). An upregulation of
anti-ROS defenses in cancer cells may explain why tumor cell lines in vitro are extremely
resistant to cytolysis by hydrogen peroxide. In addition, antiapoptotic Akt (protein kinase
B) is activated by hydrogen peroxide (Brown and Bicknell 2001). The antiapoptotic
response that can develop in response to chronic oxidative stress may have severe
implications for anticancer therapy techniques. This is because many chemotherapeutic
agents rely on the production of ROS within tumor cells to induce apoptotic mechanisms,
but if tumor cells develop a resistance to these mechanisms, chemotherapy drugs have no
method to operate, making them practically useless.
One of the final consequences of oxidative stress is an increased supply of blood
to tumor cells and the increased risk of metastasis associated with this increased blood
supply. Oxygen radicals increase tumor cell production of the angiogenic factors IL-8
and vascular endothelial growth factor (VEGF). Tumor cell oxidative stress also
promotes secretion of the matrix metalloproteinase-1 (MMP-1), a collagenase that aids
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vessel growth within the tumor microenvironment (Brown and Bicknell 2001). Oxidative
stress can, therefore, cause angiogenesis within breast carcinoma. Hypoxia and oxidative
stress may be found together within the tumor, and VEGF production within oxidatively
stressed breast carcinomas may be augmented by synergy between oxygen radicals and
tumor hypoxia. Levels of the hypoxia-inducible factor-1 (HIF-1) may be increased by
oxygen radicals, implying that oxidatively stressed carcinoma cells might show increased
HIF-1 induction during hypoxia and therefore produce more VEGF (Brown and Bicknell
2001). Oxidative stress is also thought to increase the blood supply to breast carcinoma
by triggering vasodilatation. Hydrogen peroxide induces inducible nitric oxide synthase
(NOS) in cytokine stimulated rat pleural mesothelial cells, raising the possibility that
oxidatively stressed breast tumor cells might show increased expression of inducible
NOS (Brown and Bicknell 2001). The nitric oxide produced would activate cGMP within
nearby smooth muscle cells, leading to vasodilatation. Vasodilatation could also be
triggered by carbon monoxide, because oxidative stress powerfully induces heme
oxygenase-1, which degrades heme to biliverdin and carbon monoxide. Carbon
monoxide, like nitric oxide, activates cGMP (Brown and Bicknell 2001). The increased
angiogenesis within the breast tumor microenvironment also increases the risk of bloodborne metastasis. Angiogenesis may promote lymphatic dissemination, a common
occurrence in breast carcinoma, by elevating tumor interstitial pressure (Brown and
Bicknell 2001). However, these are not the only mechanisms by which oxidative stress
can aid tumor spread. Oxygen radicals may potentially augment tumor cell migration,
increasing the risk of invasion and metastasis. The p38 MAPK is activated by oxidative
stress, and the phosphorylation of heat shock protein-27 by p38 MAPK induces changes
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in actin dynamics. Phosphorylated heat shock protein-27 promotes the migration of
MDA-MB-231 breast cancer cells on laminin-5 in vitro (Brown and Bicknell 2001). As
noted earlier, Rac1 can activate the NADPH-oxidase in tumor cells, causing superoxide
production, and ROS mediate the role of Rac1 in actin cytoskeleton reorganization
(Brown and Bicknell 2001). Oxidative stress within breast tumors may also facilitate
invasion and metastasis by activating MMPs and inhibiting protease inhibitors. The
MMP-2 is a gelatinase that is believed to play a major role in breast cancer invasion and
metastasis. High levels of MMP-2 correlate with poor prognosis in breast cancer patients
and active MMP-2 is detected more frequently in malignant than in benign breast tumors.
ROS activate MMP-2, possibly by the reaction of oxygen radicals with thiol groups
within MMP-2 (Brown and Bicknell 2001). Protease inhibitors, such as α1-proteinase
inhibitor and plasminogen activator inhibitor, may be inactivated by oxidation of
methionine residues at their active sites. This facilitates the activity of various proteases,
increasing invasion and the likelihood of metastasis. For example, plasminogen activator
is believed to play a role in metastasis (Brown and Bicknell 2001). Murine mammary
carcinoma cells that are exposed to sublethal oxidative stress exhibit decreased
attachment to immobilized laminin and fibronectin. Reduced tumor cell adhesion to
basement membrane components increases the probability that the cells will detach and
enter the blood vessels or lymphatic system (Brown and Bicknell 2001). In addition,
treatment of these cells with hydrogen peroxide, before intravenous injection into mice,
enhanced lung metastasis formation. This implies that oxidative stress may aid the
seeding of metastatic tumor cells. Finally, ROS within the tumor microenvironment may
promote metastasis by increasing vascular permeability, either by direct damage to

29

endothelial cells or by the upregulation of inducible NOS and heme oxygenase-1
previously proposed (Brown and Bicknell 2001).
Oxidative stress can occur and their associated consequences have been
discussed, it is important to examine how oxidative stress can be quantified via
biomarkers indicative of oxidative stress levels. Biomarkers of oxidative stress have been
investigated for their association with the development and progression of several cancer
types, in particular breast cancer. Oxidative stress mechanisms may be involved in
several known breast cancer risk factors, including obesity and daily alcohol intake, and
circulating estrogen levels. Breast cancer cells are susceptible to oxidative damage and
have high levels of oxidative stress, including protein damage, DNA damage, and lipid
peroxidation. In addition, several breast cancer risk factors may alter levels of
endogenous oxidative stress (Lee et al. 2017). Biomarkers of oxidative stress have been
investigated for their association with the development and progression of several cancer
types, and in particular breast cancer, as oxidative stress mechanisms may be involved in
several known breast cancer risk factors, including obesity and daily alcohol intake, and
circulating estrogen levels. Lee et al. 2017). Some studies have reported that higher levels
of oxidative stress are associated with obesity and adipose tissue. The finding of higher
levels of oxidative stress and increased risk of postmenopausal breast cancer could reflect
the known obesity and postmenopausal breast cancer association. Analyses conducted
and stratified by BMI found a positive association among women with higher BMI, but
not among women with lower BMI (Lee et al. 2017). In addition to its role in cancer cell
biology, oxidative stress plays a critical role in cancer treatment, with cytotoxic therapies
increasing oxidative damage to potentially kill tumor cells. Beyond cancer treatment,
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oxidative stress from endogenous (e.g., metabolism, immune response) and exogenous
sources (e.g., ionizing radiation, smoking, chemicals) may result in changes in the
metabolic pathways in tumor cells, tumor vascular networks, and tumor macrophage
infiltration. These alterations can impact not only tumor progression but also cancer cell
adaption to oxidative stress, potentially leading to increased resistance to therapy,
angiogenesis, and increased risk of metastasis. Due to the critical role of oxidative stress
mechanisms in both cancer treatment and potentially cancer metastasis, it has been
suggested that oxidative stress may be particularly important in cancer prognosis (Lee et
al. 2017).
A primary biomarker used to quantify oxidative stress is protein carbonylation.
Protein carbonylation is a form of protein oxidation typically promoted by reactive
oxygen species. It usually refers to a process that forms reactive ketones or aldehydes that
can be reacted by 2,4-dinitrophenylhydrazine (DNPH) to form hydrazones. Direct
oxidation of side chains of lysine, arginine, proline, and threonine residues, among other
amino acids, in the “primary protein carbonylation” reaction produces DNPH detectable
protein products (Suzuki et al. 2010). The DNPH derivatizable protein products can also
be formed in the “secondary protein carbonylation” reaction via the addition of aldehydes
such as those generated from lipid peroxidation processes. The DNPH protein products
formed from these secondary reactions are the ones of importance. Oxidative
decomposition of polyunsaturated fatty acids initiates chain reactions that lead to the
formation of a variety of carbonyl species (three to nine carbons in length). The most
reactive and cytotoxic of these species are α,β-unsaturated aldehydes (4-hydroxy-trans-2nonenal and acrolein), di-aldehydes (malondialdehyde and glyoxal), and keto-aldehydes

31

(4-oxo-trans-2-nonenal) (Suzuki et al. 2010). Despite the biology of oxidative protein
modifications being complex and incompletely defined, protein carbonylation and
chemistry of the reactions that give rise to carbonyl groups have been well characterized.
In addition to the well-established roles of protein carbonylation in oxidative
stress, this protein oxidation process may also play roles in cell signal transduction
(Suzuki et al. 2010). This suggests that cellular regulatory mechanisms of protein
carbonylation may be complex, which might include the means to promote and eliminate
protein carbonyls in the body. While enzymatic reversal of the protein–carbonyl
modifications has not yet been detected, an enzymatic reversal mechanism for protein–
methionine sulfoxide modifications exits and may play a role in the regulation of protein
carbonylation (Suzuki et al. 2010). As protein carbonylation is irreversible though, the
modified proteins must be degraded by the cell’s proteasomal system. Cells can degrade
proteins in two different ways — ATP-ubiquitin dependent by the 26S proteasome and
ATP-ubiquitin independent by the 20S proteasome (Fedorova et al. 2013). Numerous
studies have demonstrated that oxidatively damaged proteins are degraded preferentially
by the 20S proteasome, whereas the activity of the 26S proteasome significantly
decreased during oxidative stress. Partially unfolded (oxidized or carbonylated) proteins
present hydrophobic moieties recognized by the 20S proteasome system. In severe
oxidative conditions, however, extensive protein carbonylation yields protein aggregates,
which can block the 20S proteasome (Fedorova et al. 2013). In addition to the absence of
a mechanism to reverse these modifications, cellular enzymes cannot repair carbonylated
proteins, resulting in an aggregation of carbonylated proteins. Basal levels of cellular
carbonylation are around two mmol/g protein, whereas severe oxidative conditions can
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increase this level up to threefold, which corresponds to one carbonylation site per 4,000
residues (Fedorova et al. 2013). If not eliminated, this aggregation of carbonylated
proteins will result in cell death. These pathophysiologic roles of protein carbonylation in
oxidation stress and oxidant signaling suggest that compounds, which regulate carbonyl
content, may have clinical value. An alternative strategy to the antioxidant intervention
based on compounds acting as free radical scavengers is to detoxify oxidative-derived
carbonyl reaction products. Trapping of lipid-derived reactive carbonyl species
(identified as the chemical intermediates between hyperglycemia, hyperlipidemia, and
their complications) seems to be very promising, and represents a new therapeutic target
on which the efforts of the medicinal chemists should focus in the near future (Suzuki et
al. 2010).
Many assays are available for the detection of protein carbonyls, but in order to
keep matters concise, only the method used in the experimental section of this paper will
be discussed. Highly sensitive assays for the detection of protein carbonyls involve the
derivatization of the carbonyl group with 2,4-dinitrophenylhydrazine (DNPH), which
leads to the formation of a stable 2,4-dinitrophenyl hydrazine-substituted product. The
development of the antibody against DNPH-derivatized proteins was a revolutionary step
in changing the approach to studying carbonylated proteins by allowing for the use of
immunological techniques. More recently, these methods contributed to a rapid progress
in
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carbonylated

proteins

using
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electrophoresis, followed by immunoblotting and mass spectrometry. This redox
proteomics approach allowed for the identification of carbonylated proteins in various
diseases in humans, animals models, and cell models, and has provided important
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information to biologists by describing the effects of modifications by carbonyl species
on protein function, as well as the consequences of such modifications at the cellular
level (Suzuki et al. 2010). The measurement of protein carbonyls following their covalent
reaction with DNPH has become the most widely utilized measure of protein oxidation in
several human diseases (Dalle-Donne et al. 2003). The stable DNP adduct can be
detected by various means. The DNP group itself absorbs ultraviolet light so that the total
carbonyl content of a protein or mixture of proteins can be quantified by a
spectrophotometric assay, which can be coupled to protein fractionation by highperformance liquid chromatography (HPLC) to give greater sensitivity and specificity
than measuring total carbonyls in a protein mixture (Dalle-Donne et al. 2003). However,
more work has to be done in order to identify the molecular nature of the carbonyls, that
is, which amino acid residues have been damaged and on what proteins in human tissues
and body fluids. In the last few years, the identification of carbonylated proteins has been
facilitated by the availability of commercial specific antibodies to anti-DNP that allow
their detection by immunoblotting analysis in analogy, for example, with the protocols
for the study of phosphorylated proteins. Immunoblotting assays based on the use of antiDNP antibodies have been developed in an attempt to identify oxidatively damaged
proteins in human tissues and body fluids. The carbonyl content in individual proteins is
assessed by one-dimensional (1D) or two-dimensional (2D) sodium dodecyl sulfate
(SDS) gel electrophoresis followed by Western blot immunoassay (oxyblot) (DalleDonne et al. 2003). These two methods have significantly more sensitivity and specificity
than all other total carbonyl assays, but they are only semiquantitative. In the method
previously mentioned, DNPH-derivatized proteins are separated by molecular weight
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using polyacrylamide gel electrophoresis in the presence of SDS-PAGE, blotted to an
adsorbent, porous membrane, and visualized by immunostaining with antibodies that
recognize the DNP portion of the hydrazone (Dalle-Donne et al. 2003). The Western blot
immunoassay used in this method has the advantage of avoiding complications such as
incomplete removal of the free DNPH before spectrophotometric measurement, as it
detects only DNP groups conjugated to proteins. Small amounts of free DNPH, which
may remain in a sample for electrophoresis, do not react with the anti-DNP antibodies
even if they bind to transfer membranes. Furthermore, the carbohydrate groups in
glycoproteins have no apparent effect in the assay (Dalle-Donne et al. 2003).
The purpose of this experiments conducted in this study were to assess how
effectively different compounds performed when tested for antioxidant capabilities. The
compounds used were vitamin E, CoQ10, lovastatin, and hydrogen peroxide. The
hypothesis being tested is that vitamin E, CoQ10, and lovastatin will all exhibit
antioxidant effects on the treated cancer cells, while hydrogen peroxide should cause
there to be a higher level of oxidative stress within the cells due to its oxidative nature.
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Chapter 2: Oxidative Stress-Associated Carbonylation in Breast Cancer Cells
I.) Introduction
Reactive oxygen species (ROS) are simply chemically reactive species containing
oxygen, and in a physiological context, they are natural byproducts of normal cell
metabolism. However, when reactive oxygen species reach critical levels inside of cells,
cancerous and non-cancerous cells alike experience oxidative stress, which affects
numerous biological mechanisms within these cells. Antioxidants, on the other hand, are
compounds that inhibit oxidation. Antioxidants terminate the oxidative chain reactions
that produce stress within cells, helping to maintain a homeostatic balance. Additionally,
oxidative stress levels inside cancer cells can be quantified using biomarkers that are
associated with this stress, and in this paper, protein carbonylation is the biomarker of
choice. Specifically, the experiments presented determine the level of proteins
carbonylated from lipid aldehyde groups produced from “secondary protein
carbonylation” reaction via the addition of aldehydes such as those generated from lipid
peroxidation processes. The driving force behind the experiments presented is to assess
the effectiveness of different compounds as antioxidants in reducing the level of
oxidative stress within triple-negative breast cancer cells. After cells have been incubated
in their respective compounds, oxidative stress levels will be quantified via protein
carbonylation levels observed from performing the oxyblot technique.
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II.) Materials and Methods
Cell Culture/Compound Treatment:
Human breast tumor cell line MDA-MB-231-derived subclone BoM1833 (BoM,
bone metastatic) was originally developed by the Massagué group at Memorial Sloan
Kettering Cancer Center, New York City, New York. The cells were maintained in
RPMI 1640 media with L-glutamine (2 mM) (Corning), supplemented with fetal bovine
serum [FBS, 10% (v/v), Hyclone], penicillin (50 units/mL) and streptomycin (50 µg/mL)
(Lonza) and normacin (2 µg/mL) (Invivogen). For method development, two previously
collected BoM cell pellet samples were used (passage #11 and #7, respectively, stored at
−20°C). To quantify the effects of compound treatment on protein carbonylation, BoM
cells were seeded at the density of 0.5 x 106 cells/mL in a volume of 1 mL/well of 12well plate. After overnight incubation in a humidified environment (5% CO2:95% Air) at
37°C, cells were washed once with RPMI 1640, and then 0.5 mL of RPMI 1640 with
FCS (10%) and antibiotics were added to each well. Compounds were prepared as stock
solutions in DMSO (except H2O2) and diluted with the serum- and antibiotic-free RPMI
1640. The working solutions containing compounds were added to the wells in a volume
of 500 µL to achieve the specified final concentrations. For control wells, 500 µL of
serum- and antibiotic-free RPMI 1640 were added. Cells were then incubated at 37°C for
25 hours. The layout for the 12-well plate once the compounds were added to each well is
shown in Table 1.
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Table 1: 12-well plate layout for cell cultures treated with compounds

A

B

C

1

2

3

4

Vitamin E

Vitamin E

Lovastatin

Lovastatin

10 µM

100 µM

1 µM

10 µM

CoQ10

CoQ10

H2 O2

H2 O2

1µM

10 µM

10 µM

30 µM

Media

Media

Media

H2 O2

Control

Control

Control

100 µM

Protein Extraction with MPER Protocol:
Mammalian protein extraction reagent (ThermoFisher), or MPER, is a cell lysis
reagent that dissolves cell membranes to extract and solubilize total protein from most
cell compartments. It is a reagent that works quickly and provides minimal interference
with biological applications. For the lysis of previously frozen cell pellet, a change was
made to the traditional MPER protocol. For the BOM passage #7 (P7) cell pellet sample
and half of the BOM passage #11 (P11) pellet sample, β-mercaptoethanol (1% v/v) was
added to the MPER solution. For those with β-mercaptoethanol added, a (+) designation
was added and a (–) designation to those without in order to differentiate between
samples. A master mix was created for (+) cells that consisted of 940 µL of MPER, 50 µL
of 20x protease inhibitor (Sigma), and 10 µL of β-mercaptoethanol. For (–) cells, or those
without β-mercaptoethanol, the same mixture was used but 10 µL of ddH2O was added in
place of β-mercaptoethanol. The cell pellet was washed once with serum-free RPMI1640
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media and cells pelleted by centrifugation at 2,500 x g for 10 minutes, and after, the
supernatant was discarded. P7 cells were split into two different tubes with about 90 µL
in each tubes. The appropriate master mixes were added to their respective tubes, and the
final volume of the three tubes was approximately 375 µL for each of the three tubes. As
the mixture was added, it was pipetted up and down in order to resuspend the pellet. The
three tubes were then shaken gently for 10 minutes and cell debris was removed by
centrifugation at ~14,000 x g for 15 minutes at room temperature. After centrifugation,
the supernatant of each tube was transferred to a new tube for analysis via BCA protein
assay (ThermoFisher). For the acquisition of cell lysates from cells in 12-well plate, 10x
PBS (Fisher Scientific) was diluted to 1x with ddH2O and kept on ice, and 1900 µL of
MPER was combined with 100 µL of protease inhibitor (PI). Once the two solutions were
prepared, cells in the 12-well plate previously mentioned were removed from incubation
and observed underneath the microscope, making sure to note the conditions of each
well. The condition media was then removed from each well. The cells were washed with
2 mL of ice cold 1x PBS/ well and then transferred back out, making sure to remove as
much liquid as possible. A mixture of 150 µL of MPER + PI solution was added to each
well, and the plate was kept on ice for ~10 minutes with gentle rocking. The cell lysates
were then scraped from each well, transferred to individual, cooled tubes, and centrifuged
at 10,000 xg for 5 minutes. The supernatant from each tube was then transferred to a new,
cooled tube. The protein concentration in each sample is determined by the BCA protein
assay.
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Protein Concentration and Quantification
Once the proteins had been extracted using the MPER protocol, the samples were
analyzed using a micro BCA protein assay kit. The standards were prepared from a 2
mg/mL BSA stock solution, and a working reagent was made from the three solutions
provided: 1400 µL of MA, 1344 µL of MB, and 56 µL of MC solutions, which is at a
25:24:1 ratio. The three solutions were combined to make a total volume of 2800 µL.
Each well contained 100 µL of sample or standard and 100 µL of working reagent for
200 µL total in each well. Additionally, the method in which the dilutions of the
standards were achieved can be observed in Table 2, and the dilutions for the samples
were achieved in a similar method. The plate layout of the 96-well plate can be seen in
Table 3. After the dilutions were completed, the samples added, and the working reagent
was added, the plate was incubated at 37 °C for 2 hours. After it was allowed to cool to
room temperature, the plate was read at 562 nm. The concentration readings observed
after normalization for background interference (620 nm) can be observed in the results
section in Table 5. Using the OD 562 values obtained from analysis of the protein
standards, a graph was created from plotting protein standard concentrations vs. OD 562
using a linear regression trendline in order to determine the concentration of the protein
in each sample. The graph and associated trendline can also be viewed in the results
section in Figure 1.
Table 2: Dilutions of BCA Standards
Tube

BSA Standard

Volume of Standard

Volume of ddH2O

Concentration

(µL)

(µL)

(µg/mL)

40

A

40

10 (Stock)

490

B

30

7.5 (Stock)

492.5

C

20

250 (Tube A)

250

D

15

250 (Tube B)

250

E

10

250 (Tube C)

250

F

7.5

250 (Tube D)

250

G

5

250 (Tube E)

250

H

0

0

250

Table 3: Layout of 96-well plate for first BCA protein assay experiment

A

1 (BSA)

2

3

4

5

0

P7 (+) 1:10

P11 (-) 1:10

P7 (+) 1:100

“Solvent”
1:100

B

5

P7 (+) 1:20

P11 (-) 1:20

P7 (+) 1:200

“Solvent”
1:200

C

7.5

P7 (+) 1:40

P11 (-) 1:40

P7 (+) 1:300

“Solvent”
1:300

D

10

P7 (+) 1:100

P11 (-)

P7 (+) 1:400

1:100
E

15

P11 (+) 1:10

MPER + PI
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“Solvent”
1:400

P11 (+)

F

G

H

20

30

40

1:10

1:100

MPER + PI

P11 (+)

1:20

1:200

MPER + PI

P11 (+)

1:40

1:300

P11 (+)

MPER + PI

P11 (+)

1:100

1:100

1:400

P11 (+) 1:20

P11 (+) 1:40

For the second BCA protein assay experiment, the BCA standards and their dilutions
were performed in the same method as shown in Table 2, and the working solution for
this round was again made using the three master solutions provided. 1500 µL of MA,
1440 µL of MB, and 60 µL of MC were combined to make a final volume of 3000 µL.
The plate layout for the standards and samples of this experiment are shown in Table 4.
As with the previous round, 100 µL of sample/standard and 100 µL of working solution
were added to each well. The 96-well plate was incubated at 37 °C for 1 hour and 47
minutes. The plate was then read at 562 nm. As before, the concentration readings
observed after normalization for background interference can be observed in the results
section in Table 6. Using the OD 562 values obtained from analysis of the protein
standards, another graph was created from plotting concentration vs. OD 562 using a
linear regression trendline in order to determine the concentration of the protein in each
sample. The graph and associated trendline can also be viewed in the results section in
Figure 2.
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Table 4: Layout of 96-well plate for second BCA protein assay experiment

A

B

C

D

E

7 (1:50)

8 (1:50)

9 (BCA)

10 (1:100)

11 (1:200)

12

Vitamin E

H2O2 10

0

Vitamin E

Vitamin E

H2O2 10 µM

10 µM

µM

10 µM

10 µM

(1:100)

Vitamin E

H2O2 10

Vitamin E

Vitamin E

H2O2 10µM

100 µM

µM

100 µM

100 µM

(1:200)

Lovastatin

MPER

Lovastatin

Lovastatin

MPER + PI

1 µM

+PI

1 µM

1 µM

(1:100)

Lovastatin

MPER +

Lovastatin

Lovastatin

MPER +PI

10 µM

PI

10 µM

10 µM

(1:200).

CoQ10

CoQ10

1µM

1µM

CoQ10

CoQ10

10 µM

10 µM

CoQ10

5

7.5

10

15

1µM
F

CoQ10

20

10 µM
G

MC 1

30

MC 1

MC 1

H

MC 2

40

MC 2

MC 2

Table 5: Protein concentration readings (µg/mL) at 562 nm from first BCA protein assay
(correlating to Table 3).
1

2

3

4

5

A

0

3.875

1.912

2.632

3.875

B

0.074

3.875

1.27

1.499

3.852

C

0.104

3.875

0.797

0.903

3.055
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D

0.170

2.347

0.392

0.700

2.438

E

0.229

3.875

0.052

1.876

-

F

0.339

3.875

0.034

0.982

-

G

0.418

3.875

3.875

0.672

-

H

0.685

2.394

3.875

0.488

-

In Table 5, the results obtained from the first BCA protein assay are shown. The
readings observed in the table are the concentration (µg/mL) of the protein samples, and
the purpose of obtaining these concentrations was so the amount of protein in each
sample could be normalized for the oxyblot experiment. However, only the bolded values
in Table 5 could be used because the rest of the protein concentrations were outside of the
range of the protein standards given in column 1.

Protein Concentration Standard
0.500

OD 562

0.400

y = 0.0682x - 0.0821

0.300
0.200
0.100
0.000
-0.100

0

5

7.5
10
15
20
Protein Concentration (μg/mL)

30

Figure 1: Protein standard concentration vs. OD 562 in first BCA protein assay
Using the concentration of the viable protein standards from Table 5, a graph
plotting the protein concentration against OD 562 was created, and a line of best-fit using
linear regression was used to give us the formula observed in Figure 1. From this
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formula, the amount of actual protein in each sample was calculated, and this was a
crucial step for the oxyblot experiments performed because the same amount of protein
was required in each sample for the results to be accurate.

Table 6: Protein concentration (µg/mL) readings at 562 nm from second BCA protein
assay (correlating to Table 4).
7

8

9

10

11

12

A

0.217

5 x 10-3

0

0.124

0.063

2 x 10-3

B

0.205

-

0.075

0.074

0.030

-

C

0.208

-

0.085

0.111

0.054

5 x 10-3

D

0.189

-

0.11

0.108

0.072

-

E

0.229

-

0.181

0.144

0.064

-

F

0.235

-

0.240

0.114

0.058

-

G

0.190

-

0.123

0.123

0.064

-

H

0.197

-

0.120

0.120

0.061

-

The results from the second BCA protein assay experiment are shown in Table 6.
Again, the purpose of obtaining these values was so that normalization of the amount of
protein present in each sample during the subsequent oxyblot could be performed. Unlike
the first protein assay, the majority of the sample concentrations fell within the range of
the standards, and they can be seen in bold in Table 6. Because the number of lanes in the
SDS-PAGE gel limited us to twelve, the highest concentration of each sample that fell
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within the standard range was used. In using the highest available concentration of each
sample, the effects of the compounds could be better observed in the oxyblot experiment.

Protein Concentration Standard
OD 562

0.600
y = 0.0513x - 0.06

0.400
0.200
0.000
-0.200

0

5

7.5

10

15

20

30

40

Protein Concentration (μg/mL)

Figure 2: Protein concentration vs. OD 562 graph in second BCA protein assay
Using the viable concentrations gathered from Table 8, the graph in Figure 3 was
created by plotting the protein standard concentrations against OD 562, and after this had
been completed, a line of best fit using the linear regression method was added in order to
obtain the formula observed in Figure 3. Again, this formula is crucial for ensuring an
equal amount of protein is present in each sample during the oxyblot technique.
Oxyblot
The oxyblot technique consists of a multistep protocol that involves a
derivatization reaction, separation of proteins by SDS-PAGE, transfer onto a membrane,
incubation with necessary antibodies, and exposure to film. A commercial kit (Millipore)
was used to detect protein carbonylation. Two rounds of oxyblot were performed, and the
first step in the process is the derivatization reaction. For the derivatization reaction, two
tubes of each sample are used. The purpose of this is to provide a negative control and a
non-control sample. Using the data collected from the BCA protein assay, the amount of
protein in each sample was calculated, and this was done to standardize the amount of
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protein that would be used for the reaction. For the first round of oxyblot, 7.0 µL of
protein was used for the lowest protein concentration sample, which was P11 (-). 1.2 µL
was used for P7 (+), and 1.5 µL was used for P11 (+), and the final amount of protein in
all samples was approximately 5 µg in a total volume of 7 µL. For the two higher
concentration samples, MPER made up the rest of the missing volume. For all samples, 3
µL of 20% SDS were also used. For negative control samples, 10 µL of derivatization
control were added, and for non-control, 10 µL of DNPH were added. After all samples
incubated at room temperature for 15 minutes, 7.5 µL of neutralizing solution was added
to each.
Preparation for gel loading was the next step in the protocol. A gel loading buffer
was created in preparation for gel loading. The gel-loading buffer consisted of 190 µL of
Laemmli 2x sample buffer (Bio-Rad) and 10 µL of β-mercaptoethanol. For the molecular
weight standards, 10 µL of 2x loading buffer and 10 µL of pre-stained molecular weight
standards was used. For the oxyblot standard, 2.5 µL of standard, 7.5 µL of ddH2O, and
10 µL of 2x loading buffer were added. For the samples, 15 µL of sample and 15 µL of
2x loading buffer were added to each well. Once all the samples and standards were
prepped, they were ready to load in the gel. The gel was then loaded and run at 70 volts
for 20 mins, 57 volts for 1 hour, and 22 volts for 40 minutes in a Tris-Hepes-SDS running
buffer. The layout of the gel lanes can be viewed in Table 7. The proteins were then
electroblotted to a nitrocellulose membrane. An electroblot transfer buffer was prepared
using 100 mL of 10x TG buffer, 100 mL of methanol, and 800 mL of ddH2O. The
transfer ran at ~140 milliamps for 40 minutes, 150 for 20 minutes, and 50 for 15 minutes.
Once the transfer had been completed, the nitrocellulose membrane was blocked

47

overnight at 4°C in a 1% BSA/PBS-T buffer. The PBS-T was prepared by combining 50
mL of 10x PBS, 0.25 mL of Tween-20, and 449.75 mL of ddH2O. This was then used to
make the blocking buffer by combining 0.902 g of BSA with 90 mL of PBS-T. The
blocking buffer was then poured off, and 1:150 solution consisting of 60 µL of primary
antibody (Millipore) and 9 mL of blocking buffer. The membrane was incubated in the
solution for approximately one hour at room temperature with gentle shaking. It was then
rinsed twice with 1x PBS-T, washed with 1x PBS-T once for 15 minutes, and then twice
for five minutes each. A 1:300 solution consisting of 30 µL of secondary antibody
(Millipore) and nine mL of blocking buffer were added to the membrane, and the
membrane was incubated for another hour at room temperature, with gentle shaking. It
was then washed as previously explained and placed protein side up and covered to
prevent light from hitting it. SuperSignal West Femto Maximum Sensitivity Substrate
was used as the chemiluminescent reagent. The membrane was incubated in this reagent
for 1 minute, and then, the excess reagent was drained off. The membrane was then
placed protein side up in the film cassette and exposed for approximately thirty seconds
to develop.
For the second round of oxyblot, the protocol was performed in the same manner
as previously described, but different chemicals were used. For the derivatization
reaction, H2O2 had the lowest protein concentration, so 7.0 µL were used. For the other
samples, media control used 2.8 µL, 100 µM Vitamin E used 3.8 µL, 10 µM CoQ10 used
3.0 µL, and 10 µM lovastatin used 3.0 µL. As before, the missing volume needed to make
7 µL was filled in by MPER. The gel was then loaded and run at 70 volts for one hour
and 20 minutes and 100 volts for 20 minutes. The layout for the second SDS-PAGE gel
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can be seen in Table 8. The proteins were then transferred at 150 milliamps for one hour.
The membrane was then transferred into the blocking solution for one hour at room
temperature, and the primary and secondary antibodies were added in the same method as
before and all other steps were the same as previously described.

Table 7: Lane layout for first SDS-PAGE gel
Lane 1

Lane 2

Lane 3

Lane 4

Lane 5

Lane 6

Lane 7

Lane 8

Molecular Oxyblot

P11 (+)

P11 (+)

P11 (-)

P11 (-)

P7 (+)

P7 (+)

Weight

Control

Standard

Control

Control

Marker

Table 8: Lane layout for second SDS-PAGE gel.
1

2

3

4

5

6

7

8

9

10

11

12

Molecular

Oxyblot

Media

Media

H2 O2

H2 O2

VE

VE

CoQ10

CoQ10

Lov

Lov

Weight

Standard

Control

Control

Control

Control

Control

Marker

III.)

Results
The following is the results gathered from each individual experiment. The results

consist of Figure 3 and Figure 4, which show the gels obtained from the oxyblot
experiments performed.
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Oxyblot

P11 (+)
(-)
(+)

P11 (-)
(-)
(+)

P7 (+)
(-)
(+)

97.4 kDa è
68 kDa è
43 kDa è
29 kDa è
21 kDa è

Figure 3: Effects of extraction conditions on breast cancer cell carbonylation
Figure 3 shows the results from the first oxyblot experiment. The primary purpose
of this experiment was to perfect the oxyblot protocol in addition to observing the effects
of adding β-mercaptoethanol to the samples. It was observed that samples containing βmercaptoethanol exhibited no results for protein carbonylation, but the opposite was
observed for the sample without β-mercaptoethanol, with it blurring into the surrounding
lanes
Oxyblot

Media
(-)
(+)

H 2O 2
(-)
(+)

Vitamin E
(-)
(+)

CoQ10
(-) (+)

Lovastatin
(-)
(+)

43 kDa è
29 kDa è

Figure 4: Impact of antioxidants and oxidants on carbonylation in breast cancer cells
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Figure 4 shows the results from the second oxyblot experiment. The lanes labeled
(-) were the negative control samples, and the (+) labeled lanes are the samples that
should exhibit protein carbonylation. Observation of Figure 4 shows low levels of protein
carbonylation at proteins with a molecular weight of 29 kDa and 63 kDa in the media,
CoQ10, and lovastatin samples but nothing particularly significant. Although hydrogen
peroxide is known to induce an increase in oxidative stress levels, no protein
carbonylation was present in the oxyblot. This is most likely due to the cells being
severely degraded by the compound treatment, which resulted in the death of most of
them. However, the vitamin E sample in Figure 4 shows high levels of protein
carbonylation at these proteins, which is indicative of increased oxidative stress within
the cells.
IV.) Discussion
The protein carbonylation levels in the media control sample were expected and
were used as a baseline of normal cancer cell levels of oxidative stress within cancer
cells. From the level of protein carbonylation exhibited by the media sample, the relative
increase or decrease in protein carbonylation can inferred. For hydrogen peroxide, there
should have been severe levels of protein carbonylation, as it is known to induce high
levels of oxidative stress, but because the cells were mostly dead upon retrieval from
plate, the sample did not work well for this experiment. For CoQ10 and lovastatin, the
samples did not experience a significant increase or decrease in the level of protein
carbonylation relative to the media control. But, CoQ10 is considered to exhibit
antioxidant capabilities according to Portakal et al. (2000). Furthermore lovastatin is
thought to have some degree of antioxidant capacity as well according to data from
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Kumar et al. (2011). The most intriguing finding from the experiments presented is the
level of protein carbonylation induced by vitamin E in breast cancer cells. Vitamin E has
been used for as an antioxidant for several experiments, and as a result, there is literature
assessing its effectiveness as an antioxidant. In some cases, vitamin E is shown to reduce
the oxidative stress within cells, thereby decreasing the level of protein carbonylation.
When vitamin E is present with lipids in the cell membrane, it works to inhibit cancer
formation through the neutralization of ROS. A direct relationship was also established
between vitamin E deficiencies and lipid peroxide production (Nathan et al. 2011). In
addition, vitamin E and epicatechin treatment appeared to ameliorate the effects of toxic
oxidative stress induced by nicotine by scavenging free radicals and enhancing the effects
of antioxidant enzymes (Al-Malki and Moselhy 2013). Data collected by Garibaldi et al.
1994 also suggests the involvement of tocopherols, such as vitamin E, in the prevention
of oxidative damage by of circulating proteins. Considering the literature in favor of
vitamin E’s effectiveness as an antioxidant, it was interesting that the cells treated with
vitamin E expressed higher levels of protein carbonylation than was present in the media
control. Although there is no definitive answer for this, one possible reason is vitamin E,
in high doses, may exhibit prooxidative qualities (Kodentsova et al. 2013). Therefore, the
prooxidative qualities induced by vitamin E could result in the increase of oxidative
species within the cell, which would result in the enhanced level of protein carbonylation
observed in Figure 4.
V.) Conclusion
In conclusion, several different compounds were assessed for their effects as
antioxidants during the experiments presented. Although the majority of compounds did
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not produce significant results, vitamin E surprisingly exhibited an oxidant, not
antioxidant, capacity. This result is interesting because vitamin E is a compound
traditionally considered to have antioxidant qualities, but the findings presented in this
study present a different picture. Although the results from these experiments are not
definitive, they do provide a different perspective on the compounds used and their
ability to reduced oxidative stress and lower protein carbonylation levels. In order to help
these results become more definitive, the experiments should be repeated with another
two gels, and in addition to running two more gels, imageJ software could be used to
quantify the concentration in each band.
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